

Foster Lab Publications:

1. **Foster DA**, Spangler R, and Zubay G. (1981). Inhibition of host DNA synthesis by adenovirus infection is reversed at elevated temperatures. *J. Virol.* 37, 493-495. P
MCID: PMC171027
2. **Foster DA**. (1981). 1-β-D-Arabinosylcytosine stimulates thymidine incorporation into the DNA of contact-inhibited cells. *Exp. Cell Res.* 135, 427-431.
3. **Foster DA**, Hantzopoulos P, and Zubay G. (1982). Resistance of adenoviral DNA replication to aphidicolin is dependent on the 72-kilodalton DNA-binding protein. *J. Virol* . 43, 679-686.
PMCID: PMC256170
4. **Foster DA**, and Hanafusa H. (1983). A *fps* gene without *gag* gene sequences transforms cells in culture and induces tumors in chickens. *J. Virol* . 48, 744-751.
PMCID: PMC255406
5. **Foster DA**, Shibuya M, and Hanafusa H. (1985). Activation of the transformation potential of the cellular-*fps* gene. *Cell.* 42, 105-115.

PMCID: PMC367515

6. **Foster DA**, Levy JB, Daley GQ, Simon MC, and Hanafusa H. (1986). Isolation of chicken cellular DNA sequences with homology to the region of viral oncogenes that encodes the tyrosine kinase domain. *Mol. Cell. Biol.* 6, 325-331.

7. Spangler R, Joseph C, Qureshi S, Berg KL, and **Foster DA**. (1989). Evidence that v-src and v-fps gene products use a protein kinase C-mediated pathway to induce expression of a transformation-related gene.

Proc. Natl. Acad. Sci. USA
86, 7017-7021.
PMCID: PMC297983

8. Qureshi SA, Alexandropoulos K, Joseph CK, Spangler R, and **Foster DA**. (1991). Cholera toxin induces expression of the immediate-early response gene, JE, via a cAMP-independent signaling pathway.

Mol. Cell. Biol
. 11, 102-107.
PMCID: PMC359597

9. Qureshi SA, Joseph CK, Rim M-H, Maroney A, and **Foster DA**. (1991). v-Src Activates Both Protein Kinase C-Dependent and Independent Signaling Pathways in Murine Fibroblasts. *Oncogene*
. 6, 995-999.

10. Qureshi SA, Cao X, Sukhatme VP, and **Foster DA**. (1991). v-Src Activates Mitogen-responsive Transcription Factor Egr-1 via Serum Response Elements. *J. Biol. Chem*
. 266, 10802-10806.

11. Alexandropoulos K, Joseph CK, Spangler R, and **Foster DA.** (1991). Evidence for the Involvement of a G-Protein in signals initiated by the protein-tyrosine kinase v-Fps.

J. Biol. Chem

. 266, 15583-15586.

12. Song J, Pfeffer LM, and **Foster DA.** (1991). v-Src Increases Diacylglycerol levels via a yype D phospholipase-mediated hydrolysis of phosphatidylcholine.

Mol. Cell. Biol

. 11, 4903-4908.

PMCID: PMC361459

13. Qureshi SA, Rim M, Bruder J, Kolch W, Rapp U, Sukhatme VP, and **Foster DA.** (1991). An inhibitory mutant of c-Raf-1 blocks v-Src-induced activation of the Egr-1 promoter.

J. Biol. Chem

. 266, 20594-20597.

14. Qureshi SA, Rim M, Alexandropoulos K, Berg K, Sukhatme VP, and **Foster DA.** (1992). Sustained induction of Egr-1 by v-Src correlates with a lack of Fos-mediated repression of the Egr-1 promoter.

Oncogene

.

7, 121-125.

15. Joseph CK, Qureshi SA, Wallace DW, and **Foster DA.** (1992). MARCKS protein is transcriptionally down-regulated in v-Src-transformed BALB/c 3T3 cells.

J. Biol. Chem

. 267, 1327-1330.

16. Alexandropoulos K, Qureshi SA, Sukhatme VP, and **Foster DA.** (1992). v-Fps-responsiveness in the Egr-1 promoter is mediated by serum response elements.

Nuc. Acid Res

.

9

, 2355-2359.

PMCID: PMC312353

17. Maroney AC, Qureshi SA, **Foster DA**, and Brugge JS. (1992). Cloning and characterization of a thermolabile *v-src* gene for use in reversible transformation of mammalian cells.
Oncogene
7, 1207-1214.

18. Rim M, Qureshi SA, Gius D, Nho J, Sukhatme VP, and **Foster DA**. (1992). v-Raf activates the Egr-1 promoter through serum response elements.
Oncogene
. 7, 2065-2068.

19. Qureshi SA, Alexandropoulos K, Joseph CK, Rim M, Bruder J, Rapp UR, and **Foster DA**. (1992).

Evidence that HaRas mediates two distinct intracellular signals activated by v-Src.

J. Biol. Chem
. 267

,
17635-17639.

20. Alexandropoulos K, Qureshi SA, Bruder J, Rapp UR, and **Foster DA**. (1992). The induction of the Egr-1 promoter by v-Fps is via a PKC-independent intracellular signal that is sequentially dependent upon HaRas and Raf-1.

Cell Growth and Differ
. 3, 731-737.

21. Alexandropoulos K, Qureshi SA, and **Foster DA**. (1993). HaRas functions downstream from protein kinase C in v-Fps-induced gene expression mediated by TPA response elements

.
Oncogene
. 8, 803-807.

22. Qureshi SA, Joseph CK, Gupta R, Hendrickson M, Song J, Bruder J, Rapp U, and **Foster DA**.

(1993). A dominant-negative Raf-1 mutant prevents v-Src-induced transformation.

Biochem. Biophys. Res. Comm

. 192, 969-975.

23. **Foster DA**. (1993). Intracellular signalling mediated by protein-tyrosine kinases: Networking through phospholipid metabolism.

Cell. Signalling

. 5,

389-399.

24. Song J, and **Foster DA**. (1993). v-Src activates a phospholipase D activity that is distinguishable from phospholipase D activity activated by protein kinase C.

Biochem. J

. 294, 711-717.

PMCID: PMC1134521

25. Gupta, R., Joseph, C.K., and Foster, D.A. (1993). v-Src-induced transformation is inhibited by okadaic acid. Biochem. Biophys. Res. Comm. 196, 320-327.

26. Song J, Jiang Y-W, and **Foster DA**. (1994). EGF induces the production of biologically distinguishable diglyceride species from phosphatidylinositol and phosphatidylcholine: Evidence for the independent activation of type C and type D phospholipases.

Cell Growth and Differ

. 5, 79-85.

27. Chao T-SO, **Foster DA**, Rapp UR, and Rosner MR. (1994). Differential Raf-1 requirement for activation of mitogen-activated protein kinase by growth factors, phorbol esters

and calcium.

J. Biol. Chem. 269, 7337-7341.

28. Jiang H, Alexandropoulos K, Song J, and **Foster DA**. (1994). Evidence that v-Src-induced phospholipase D activity is mediated by a G-protein.

Mol. Cell. Biol.

.
14,
3676-3682

.
PMCID: PMC358735

29. Jiang Y-W, Song J, Zang Q, and **Foster DA**. (1994). Phosphatidylcholine-specific phospholipase D activity is elevated in v-Fps-transformed cells.

Biochem. Biophys. Res. Comm

. 203,1195-1203

30. Gupta R, and **Foster DA**. (1994). Differential effects of protein phosphatase 2A on distinguishable intracellular signals initiated by v-Src and mediated by HaRas.

Biochem. Biophys. Res. Comm

. 205, 1043-1050.

31. Jiang H, Lu Z, Luo JQ, Wolfman A, and **Foster DA**. (1995). Ras mediates the activation of phospholipase D by v-Src.

J. Biol. Chem

270, 6006-6009.

32. Mukhopadhyay D, Tsiokas L, Zhou XM, **Foster DA**, Brugge JS, and Sukhatme VP. (1995). Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation.

Nature. 375, 577-580.

33. Zang Q, Frankel P, and **Foster DA**. (1995). Selective activation of protein kinase C isoforms in v-Src-transformed BALB/c 3T3 cells.

Cell Growth Differ

Cell

. 6, 1367-1373

.

34. Jiang H, Luo JQ, Urano T, Frankel P, Lu Z, **Foster DA***, and Feig LA. (1995).
Involvement of Ral GTPase in v-Src-induced Phospholipase D activation.

Nature

. 378, 409-412. (*Corresponding author).

35. Spiegel S, **Foster DA.** and Kolesnick R. (1996). Signal transduction through lipid second
messengers. Curr. Op. Cell Biol. 8, 159-167.

36. Jiang YW, Lu Z, Zang Q, and **Foster DA.** (1996). Regulation of phosphatidic acid
phosphohydrolase by EGF: Reduced association with the EGF receptor followed by increased
association with protein kinase C e. J. Biol.

Chem

271, 29529-29532.

37. Zang Q, Lu Z, Curto M, Barile N, Shalloway D, and **Foster DA.** (1997). Interaction
between v-Src and protein kinase C
d
in v-Src-transformed fibroblasts.

J. Biol. Chem

. 272, 13275-13280

.

38. Lu Z, Hornia A, Jiang YW, Frankel P, Zang Q, Ohno S, and **Foster DA.** (1997).
Tumor-promotion by depleting cells of protein kinase C

d

.

Mol. Cell Biol

..

17, 3418-3428

.

PMCID: PMC232195

39. Luo JQ, Liu X, Hammond SM, Colley WC, Feig LA, Frohman MA, Morris AJ, and **Foster DA.** (1997). Ral interacts directly with the Arf-responsive PIP2-dependent phospholipase D1. *Biochem. Biophys. Res. Comm*. 235, 854-859.
40. Curto M, Carrero A, Frankel P, and **Foster DA.** (1997). Activation of gene expression by a non-transforming unmyristylated-SH3-deleted mutant of Src is dependent upon Tyr-527. *Biochem. Biophys. Res. Comm*. 239, 681-687.
41. Lu, Z., Liu, D., Hornia, A., Devonish, W., Pagano, M., and **Foster, D.A.** (1998). Activation of protein kinase C triggers its ubiquitination and degradation. *Mol. Cell. Biol*. 18, 839-845.
PMCID: PMC108795
42. Curto, M., Frankel, P., Carrero, A., and **Foster, D.A.** (1998). Novel recruitment of Shc, Grb2, and Sos by fibroblast growth factor receptor-1 in v-Src-transformed cells. *Biochem. Biophys. Res. Comm*. 243, 555-560.
43. Luo, J.-Q., Liu, X., Frankel, P., Rotunda, T., Ramos, M., Flom, J., Jiang, H., Feig, L.A., Morris, A, Kahn, R.A. and **Foster, D.A.** (1998). Functional association between RalA and Arf in active phospholipase D complexes. *Proc. Natl. Acad. Sci. USA*. 95, 3632-3637.
PMCID: PMC19887

44. Frankel, P.A., Ramos, M., Flom, J., Bychenok, S., Joseph, T., Kerkhoff, E., Rapp, U.R., Feig, L.A., and **Foster, D.A.** (1999). Ral and Rho dependent activation of phospholipase D in v-Raf transformed cells. *Biochem. Biophys. Res. Comm.* 255, 502-507

45. Corbit, K.C., **Foster, D.A.**, Rosner, M.R. (1999). PKC δ mediates neurogenic, but not mitogenic activation of MAP kinase in neuronal cells.

Mol. Cell. Biol

19, 4209-4218.

PMCID: PMC104380

46. Aguirre Ghiso, J., Frankel, P., Lu, Z., Jiang, H., Farias, E., Olsen, A., Feig, L.A., Bal de Kier Joffe, E., and **Foster, D.A.** (1999). RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator and metalloproteases. *Oncogene* 18, 4718-4725.

47. Hornia, A., Lu, Z., Sukezane, T., Zhong, M. Joseph, T., Frankel, P., and **Foster, D.A.** (1999). Antagonistic effects of protein kinase C

α

and

δ

on both transformation and phospholipase D activity mediated by the EGF receptor.

Mol. Cell. Biol

19, 7672-7680.

PMCID: PMC84804

48. Lu, Z., Hornia, A., Joseph, T., Sukezane, T., Frankel, P., (Zhong et al., 2003), M., Bychenok, S., Xu, L., Feig, L.A., and **Foster, D.A.** (2000). Phospholipase D and RalA cooperate with the EGF receptor to transform 3Y1 rat fibroblasts.

Mol. Cell. Bio

l.

20, 462-467.

PMCID: PMC85102

49. Goi, T., Shipistin, M., Lu, Z., **Foster, D.A.**, Klinz, S.G., and Feig, L.A. (2000). An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity. EMBO J

.
19, 623-630.

PMCID: PMC305600

50. Bychenok, S., and **Foster D.A.** (2000). A low MW factor from dividing cells activates phospholipase D in caveolin-enriched membrane microdomains. Arch. Biochem. Biophys

.
377, 139-145.

51. Xu, L., Shen, Y., Joseph, T., Luo, J.-Q., Frankel, P., Rotunda, T., and **Foster, D.A.** (2000). Elevated phospholipase D activity in transformed cells is restricted to caveolin-enriched membrane microdomains: Biochem. Biophys. Res. Comm

.
273, 77-83.

52. Shen, Y., Xu, L., and **Foster, D.A.** (2001). Role for phospholipase D in receptor-mediated endocytosis. Mol. Cell. Biol. 21, 595-602. PMCID: PMC86627

53. Zhong, M., Lu, Z., Abbas, T. Hornia, A., Chatakondur, K., Barile, N., Kaplan, P., and **Foster, D.A.** (2001). Novel tumor-promoting property of tamoxifen. Cell Growth Differ

.
12, 187-192.

54. Ladeda, V., Frankel P., Feig, L.A., **Foster, D.A.**, Bal de Kier Joffe, E., and Aguirre-Ghiso, J.A. (2001). RalA mediates v-Src, v-Ras and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts. Biochem

Biophy

s. Res. Comm

283, 854-861

55. Joseph, T., Wooden, R., Bryant, A., Zhong, M., Lu, Z., and **Foster, D.A.** (2001). Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2.

Biochem.

Biophys. Res. Comm

289, 1019-1024

56. Zhong, M., Lu, Z., and **Foster, D.A.** (2002). Downregulating PKCδ provides a PI3K/Akt-independent survival signal that overcomes apoptotic signals generated by c-Src overexpression.

Onco

gene

21, 1071-1078.

57. Joseph, T., Bryant, A., Wooden, R., Kerkhoff, E., Rapp, U.R. and Foster, D.A. (2002). Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling.

Oncogene

21, 3651-3658.

58. Shen, Y., Zheng, Y., and Foster, D.A. (2002). Phospholipase D2 stimulates cell protrusion in v-Src-transformed cells.

Biochem. Biophys. Res.

Comm

. 293,

201-206

59. Zhong, M., Joseph, T., Jackson, D., Beychenok, S., and Foster, D.A. (2002) Elevated phospholipase D induces apoptosis in normal rat fibroblasts.

Biochem.

Biophys. Res. Comm.

298, 474-477

60. Xu, L., Frankel, P., Jackson, D., Rotunda, T., Boshans, R.L., D'Souza-Schorey, C., and **Foster, D.A.**

(2003). Elevated phospholipase D activity in H-Ras-, but not K-Ras-transformed cells by the synergistic action of RalA and Arf6.

Mol. Cell. Biol

.
23,
645-654

.
PMCID: PMC151535

61. Zhong, M., Shen, Y., Zheng, Y., Joseph, T., Jackson, D., Beychenok, S., and Foster, D.A. (2003). Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells.

Biochem.

Biophys. Res. Comm

.
302, 615-619.

62. Chen, Y., Zheng, Y., and **Foster, D.A.** (2003). Phospholipase D confers rapamycin resistance in human breast cancer cells.

Oncogene.

22, 3937-3942.

63. **Foster, D.A.** and Xu, L. (2003). Phospholipase D in cell proliferation and cancer. Mol. Cancer Res

.
1, 789-800

64. Jackson, D., and **Foster, D.A.** (2004). The enigmatic protein kinase Cd: Complex roles in cell proliferation and survival.

FASEB J

.
18, 627-636

65. Abbas, T., White, D., Hui, L., **Foster, D.A.** and Jill Bargonetti, J. (2004). Inhibition of p53 transcription by down-regulation of protein kinase C
d
.
J. Biol. Chem
.
279, 9970-9977
.
66. Hui, L., Abbas, T., Pielak, R., Joseph, T., Bargonetti, J. and **Foster, D.A.** (2004). Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol. Cell. . 24, 5677-5688.
PMCID: PMC480910
67. Foster, D.A. (2004). Targeting mTOR-mediated survival signals in anticancer therapeutic strategies. Exp. Rev. Anticancer Ther. 4, 691-701.
68. Chen, X., Hui, L., **Foster, D.A.**, and Drain, C.M. (2004). Efficient synthesis and photodynamic activity of porphyrin-saccharide conjugates: Targeting and incapacitating cancer cells. Biochemistry, 43, 10918-10929.
69. Chen, Y., Rodrik, V. and **Foster, D.A.** (2005). Alternative phospholipase D / mTOR survival signal in human breast cancer cells. Oncogene, 24, 672-679.
70. Jackson, D., Zheng, Y., Lyo, D., Shen, Y., Nakayama, K., Nakayama, K.I., Humphries, M., Reyland, M.E., and **Foster, D.A.** (2005). Suppression of cell migration by protein kinase C
d
.
Oncogene
.
24,

3067-3072

71. Rodrik, V., Zheng, Y., Harrow, F., Chen, Y., and **Foster, D.A.** (2005). Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc . *Mol. Cell. Biol.* 25, 7917-7925.
PMCID: PMC1190308

72. Hui, L., Rodrik, V., Pielak, R.M., Zheng, Y., and Foster, D.A. (2005). mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. *J. Biol. Chem.* 280, 9-35835

73. Cai, D., Zhong, M., Wang, R., Netzer, W.J., Shields, D., Zheng, H., Sisodia, S.S., Foster, D.A., Gorelick, F.S., Xu, H., and Greengard, P. (2006). Phospholipase D1 corrects impaired β APP trafficking and neurite outgrowth in FAD-linked PS1 mutant neurons. *Proc. Natl. Acad. Sci. USA* , 103, 1936-1940.
PMCID: PMC1413666

74. Cai, D., Netzer, W.J., Zhong, M., Lin, Y., Guangwei Du, G., Frohman, M., Foster, D.A., Sisodia S.S., Xu, H., Gorelick, F.S., and Greengard, P. (2006). Presenilin-1 (PS1) utilizes phospholipase D1 as a negative regulator of β -amyloid formation. *Proc. Natl. Acad. Sci. USA* , 103, 1941-1946.
PMCID: PMC1413665

75. Zheng, Y., Rodrik, V., Toschi, A., Shi, M., Hui, L., Shen, Y., and Foster, D.A. (2006). Phospholipase D couples survival and migration signals in response to stress in human breast cancer cells. *J. Biol. Chem.*

281, 15862-15868.

76. Foster, D.A. (2006). Phospholipase D survival signals as a therapeutic target in cancer. *Current Signal Transduction Ther*

1, 295-303.

77. Rodrik, V., Gomes, E., Hui, L., Rockwell, P., and **Foster, D.A.** (2006). Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells.

FEBS Lett

580, 5647-5652.

PMCID: PMC1876739

78. Hui, L., Zheng, Y., Yan, Y., Bargonetti, J., and **Foster, D.A.** (2006). Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D.

Oncogene

25, 7305-7310.

79. Foster DA. (2007). Regulation of mTOR by phosphatidic acid? *Cancer Res.* 67, 1-4.

80. **Foster DA.** (2007). Drug resistance to rapamycin through elevated phospholipase D activity. In "Cancer drug resistance research perspectives". Nova Science Publisher, Inc. Chap IX, 139-145.

81. Mor, A., Campi, G., Du, G., Zheng, Y., Foster, D.A., Dustin, M.L., and Philips, M., (2007). The lymphocyte function associated-1 receptor co-stimulates plasma membrane Ras via phospholipase D2. *Nature Cell Biol.* 9, 713-719

82. Shi, M., Zheng, Y., Garcia, A., and Foster, D.A. (2007). Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras.

Cancer Lett

,
258, 268-275.

83. Gadir, N., Lee, E., Garcia, A., Toschi, A., and **Foster, D.A.** (2007). Suppression of TGF- β signaling by phospholipase D.

Cell Cycle

6, 2840-2845 (Featured on Journal Cover)

84. Gadir, N., Jackson, D., Lee, E., and Foster, D.A. (2008). Defective TGF- β signaling sensitizes human cancer cells to rapamycin.

Oncogene

27, 1055-1062

85. Toschi, A., Edelstein, J., Rockwell, P., Ohh, M., and **Foster, D.A.** (2008). HIF α expression in VHL deficient renal cell carcinoma cells is dependent on phospholipase D.

Oncogene

, 27, 2746-2753.

86. Garcia, A., Zheng, Y., Zhao, C., Toschi, A., Fan, J., Schreiber, N., Brown, H.A., Bar-Sagi, D., Foster, D.A.*, and Arbiser, J. (2008). Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clinical

Cancer Res

, 14, 4267-4274

PMCID: PMC2759181

*Corresponding Author.

87. Foster, D.A., and Gadir, N. (2008). Can defective TGF- β signaling be an Achilles heel in cancer? *Chinese Journal of Cancer* . 27, 882-884.
(Invited Review)
88. Thompson, S., Chen, X., Hui, L., Toschi, A. Foster, D.A., and Drain, C.M. (2008). Low Concentrations of a non-hydrolysable tetra-S-glycosylated porphyrin and low light induces apoptosis in human breast cancer cells via stress of the endoplasmic reticulum
.
Photochem Photobiol Sci
.
7, 1415-1421.
89. Toschi, A., Lee, E., Gadir, N., Ohh, M., and **Foster, D.A.** (2008). *Differential dependence of HIF1 and mTORC2. a and HIF2a on mTORC1
J. Biol. Chem
.
283, 34495-34499.
PMCID: PMC2596400
*Accelerated Publication
90. Toschi A, Lee E, Xu L, Garcia A, Gadir N, and **Foster DA.** (2009). Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid – a competition with rapamycin.
Mol. Cell. Biol.
29, 1411-1420.
PMCID: PMC2648237
91. **Foster DA,** and Toschi A. (2009). Targeting mTOR with Rapamycin: One dose does not fit all. *Cell Cycle*. 8, 1026-1029. PMCID: PMC2778016 (Invited Review)
92. **Foster DA.** (2009). Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cells. *Biochem. Biophys. Acta*. 1791, 949-955. PMCID: PMC2759177
(Invited Review)

93. **Foster DA**, and Darnell JE Jr. [Obituary: Hidesaburo Hanafusa \(1929-2009\) \(2009\)](#). *Nature* . 458, 718.

94. Roberts AM, Watson IR, Evans AG, **Foster DA**, Irwin MS, and Ohh M. (2009). Suppression of HIF2 a Restores p53 activity via HDM2 and reverses chemoresistance of renal carcinoma cells. *Cancer Res*

.
69, 9056-9064.
PMCID: PMC2789194

95. **Foster DA**. (2010). Reduced mortality and moderate alcohol consumption: The phospholipase D-mTOR connection. *Cell Cycle*. 9, 1291-1294. PMCID: PMC2957519

96. Lyo D, Xu L, and **Foster DA**. (2010). Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway. *Biochem. Biophys. Res. Comm.* 39 6, 562-565

.
PMCID: PMC3010228

97. Toschi A, Lee E, Thompson S, Gadir N, Yellen P, Drain CM, Ohh M, and **Foster DA**. (2010). Phospholipase D-mTORC2 requirement for the Warburg effect in human cancer cells. *Cancer Lett*

.
299, 72-79.
PMCID: PMC3010225

98. **Foster DA**, Yellen P, Xu L. and Saqcena M. (2010). Regulation of G1 cell cycle progression: Distinguishing the restriction point from a nutrient-sensing cell growth checkpoint. *Genes and Cancer*. 1, 1124-1131. PMCID: PMC3092273

99. Xu L, Salloum D, Saqcena M, Yellen P, Medlin PS, Perrella B, and **Foster DA**. (2011).

Phospholipase D mediates nutrient input to mTORC1.

J. Biol. Chem

.
286, 25477-25486. PMCID: PMC3138251

100. Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V, and **Foster DA**

. (2011).

[High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.](#)

Cell Cycle

10, 3948-3956. PMCID: PMC3266120

101. Yellen P, Chatterjee A, Preda A, and **Foster DA**. (2013). Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-
b

-dependent G1 cell cycle arrest.

Cancer Lett

.
333, 239-243

.
PMCID: PMC3640435

102. LeGendre O, Sookdeo A, Duliepre S-A, Utter M, Frias M, and **Foster DA**. (2013). Suppression of AKT phosphorylation restores rapamycin-mediated synthetic lethality in SMAD4-defective pancreatic cancer cells.

Mol Cancer Res

.
11

,
474

-
481

.
PMCID: PMC3640435

103. Einbond LS, Mighty J, Kasiwazaki R, Figueroa M, Jalees F, Acuna UM, LeGendre O, **Foster DA**,

Kennelly EG. (2013).

Garcinia

benzophenones inhibit the growth of human colon cancer cells and synergize with sulindac sulfide and turmeric.

Anti-Cancer Agents Med Chem

.
13, 1540-1550
.

104. **Foster DA.** (2013). Phosphatidic acid and lipid sensing by mTOR. *Trends Endocrin Metab* 24, 272-278. PMCID: PMC3669661

105. Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, and **Foster DA.** (2013). Distinct nutrient-dependent metabolic checkpoints in mammalian G1 cell cycle

.
PLoS-One

.
8, e71457

.
PMCID:
PMC3747087

106. LeGendre O, Sookdeo A, and **Foster DA.** (2014). BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition.

Oncology Lett

.
7, 1165-1168

.
PMCID: PMC3961292

107. Salloum D, Mukhopadhyay S, Tung K, Polonetskaya A, and **Foster DA.** (2014). Mutant Ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin.

Mol Cancer Ther

.
13, 733-741

.
PMCID: PMC4001122

108. **Foster DA**, Salloum D, Menon D, and Frias M. (2014). Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mTOR. *J Biol Chem.* 289, 22583-22588. PMCID: PMC4132766

109. Yellen P, and **Foster DA**. (2014). Inhibition of fatty acid synthase induces pro-survival Akt and ERK activation in K-RAS mutant cancer cells.

Cancer Lett

353, 258-263.

PMCID:

PMC4170853

110. **Foster DA**. (2014). Obituary: Geoffrey Louis Zubay (1931-2014): Pioneer in cell-free gene expression studies and molecular genetics. *Trends Biochem*

Sci

. 39, 505-506

PMCID: PMC3669661

111. **Foster DA**. (2014). Metabolic vulnerability of K-Ras-driven cancer cells. *Mol Cell Oncology*

1, e963445. PMCID:PMC4655600

112. Saqcena M, Mukhopadhyay S, Hosny, C, Alhamed AA, Chatterjee A, and **Foster DA**. (2015).

Blocking anaplerotic entry of glutamine to TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs

Oncogene

34, 2672-2680. PMCID:

PMC4418945

Epub Jul 2014.

113. LeGendre O, Breslin P, and **Foster DA**. (2015). Oleocanthol rapidly and selectively induces cell death in cancer cells via lysosomal membrane permeabilization (LMP).

Mol Cell Oncology

. 2,

e1006077

.
PMCID: PMC4568762

114. Mukhopadhyay S, Saqcena M, Chatterjee A, Garcia A, Frias MA, and **Foster, DA**. (2015). Reciprocal regulation of AMPK and phospholipase D

.
J Biol Chem

.
290

,
6986-6993

.
PMCID: PMC4358122

115. Chatterjee A, Mukhopadhyay S, Tung K, Patel D, and **Foster DA**. (2015). Rapamycin employs TGF- β and Rb pathways to cause cell cycle arrest.

Cancer Lett

.
360,
134-140

.
PMCID: PMC4415112

116. Saqcena, M, Patel D, Menon D, Mukhopadhyay S, and **Foster DA**. (2015). Apoptotic effects of high dose rapamycin occur in S-phase of the cell cycle.

Cell Cycle

.
14, 2285-2292

.
PMCID: PMC4614271

117. Foster DA, and Menon D. (2015). Phospholipase D. Encyclopedia of Cancer. In Press.

118. Mukhopadhyay S, Chatterjee A, Kogan D, Patel D, and **Foster, DA**. (2015). 5-Aminoimidazole-4-carboxamide-1- β -4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. Cell Cycle, 14, 3331-3339.
PMCID: PMC4825547

119. Mukhopadhyay S, Saqcena M, and **Foster DA**. (2015). Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation. Oncoscience, 2, 807-808.
PMCID: PMC4671930

120. Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, and **Foster DA**. (2016). The enigma of rapamycin dosage. Mol Cancer Ther, 15, 347-353.
PMCID: PMC4783198

121. Patel D, Menon D, Bernfeld S, Mroz V, Kalan S, Loayza D, Foster DA. (2016). Aspartate rescues S-phase arrest caused by suppression of glutamine utilization in KRas-driven cancer cells. J. Biol Chem. 291, 9322-9329. PMCID: PMC4861495